It is well established that T-cell help can be provided to a hapten by linking this to an amino acid sequence well recognized by MHC class II molecules ~ 6. This sequence, referred to as TD h, can also provide help even when not covalently linked to the hapten v. These findings suggested to us that an individual who fails to respond to a protein because of lack of recognition of a TDh within its sequence, might be rendered a responder by immunization with this 'haptenic' protein and a TD h peptide chosen to satisfy the class II restriction of this individual. To test this hypothesis we immunized SJL/J (H-2 s) and BI0M (H-2 f) mice, two strains of non-responders to the S region of hepatitis B surface antigen 8'9, with a recombinant surface antigen, only composed of the S region, in conjunction with a short synthetic peptide well recognized by class II molecules of SJL/J but not by those of B 10M. We provide below experimental evidence that this simple immunization strategy allows not only the manipulation of the humoral response against an 'haptenic' protein, but is also a convenient way of studying which TDh sequences are useful to potentiate the inducton of antibodies in the context of a given restriction. The results are also discussed in terms of the lack of humoral response of a small percentage of humans following immunization with the hepatitis B vaccine.
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MATERIALS AND METHODS

Antigens
The antigen used is a recombinant product (expressed in yeast cells) from Smith Kline and French, S.A. (Engerix-B) and used for vaccination in humans. It is composed only of the S region (amino acids 175-400) of the HBV surface protein. This antigen will be referred to as HBsAg. The TDh peptide FISEAIIHVLHSR (designated F1S) corresponds to amino acids 106-118 from sperm whale myoglobin of proved TDh character in Balb/c mice 1° and known to be recognized by class II molecules in SJL/J but not in B10M.
Peptide synthesis
Peptides were synthesized by the solid-phase method of Merrifield 11 using the Fmoc alternative lz. The synthesis of TDh peptide FIS was done manually and the ninhydrin test of Kaiser et al. 13 used to monitor every step. Couplings were repeated if necessary until a negative ninhydrin test was attained. FIS was purified by highperformance liquid chromatography (h.p.l.c.) on a reverse-phase C18 column. The 47 overlapping 14-mer peptides (adw z sequence) t4 from HBsAg were synthesized using a multiple solid-phase peptide synthesizer 15. They were used without further purification.
Immunization experiments
Groups of 4-week-old SJL/J (H-2 s) or B10M (H-2 f) female mice were immunized by intraperitoneal (i.p.) injection of 200 #1 of an emulsion obtained by sonication of 100#1 complete Freund's adjuvant and 100 #1 saline solution consisting of 1 #g HBsAg in 50#1 Engerix-B vaccine suspension and 50 #1 phosphate-buffered saline (PBS), or a mixture of 1 #g of this antigen and 60/~g of TD h peptide (FIS). They were boosted at day 30 and 45 with the same dose of antigen in incomplete Freund's adjuvant. Mice were bled from the retro-orbital plexus on days 30, 45 and 60 after the first injection.
Titration of antibodies
Antibodies were titrated by ELISA. Microtitre wells were coated by overnight incubation at 4°C with 50 #1 peptide solutions (20 #g ml-~ of peptide in 0.1 M sodium carbonate buffer) or with 0.1 ~g HBsAg in 50#1 0.1 M phosphate buffer, pH 7.0. Wells were then washed three times with a solution of PBS. To block non-specific antibody binding, the wells were incubated with the above buffer but containing 1% powdered milk and 0.1% Tween 20 (PBSMT) for 1 h at room temperature. After removing the PBSMT, 100 #1 of different serum dilutions in PBSMT were added and incubated at 37°C for 1 h. Wells were washed three times with PBS and then incubated at 37°C for 1 h with a 1/1000 solution of goat anti-mouse IgG biotinylated whole antibody (Amersham, UK) in PBSMT. After washing three times with PBS, wells were incubated with 1/500 dilution of horseradish peroxidase-streptavidin in PBSMT (Amersham, UK) at 3T'C for I h. After washing three times with PBS, the colour reaction was started by adding 100 #1 of a solution prepared by mixing: 10 ml 0.6% acetic acid (pH 4.7), 7.5/d of 33% (w/v) hydrogen peroxide and 100#1 of 40mM aqueous solution of ABTS (2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid). After 60 min the plates were read at 405 rim, in a Titertek Multiskan MKII (Flow Laboratories).
IL-2 production assay
Groups of three mice were immunized at the base of the tail and footpads with 1 pg free HBsAg recombinant vaccine or with 1 #g of this antigen and 60 #g of FIS in complete Freund's adjuvant (1:1). Ten days after the primary injection, animals were killed and lymph node cells removed. The lymphocytes were then plated on 96-well plates (Costar) at 5 x l0 s cells/well with RPMIsupplemented medium alone (RPMI supplemented with 10% fetal calf serum, 10mM glutamine, penicillin 100Uml ~, streptomycin 100mgml 1 and 5x10-SM 2-mercaptoethanol) or with serial dilutions of HBsAg or FIS in the same medium to a final volume of 0.2 ml. Supernatants (50 #1) were removed 24 h later and assayed for the IL-2 content using the CTL-L bioassay as described ~6. Results are presented as stimulation index, which is the ratio of the mean (three determinations) counts rain 1 incorporated in the presence of antigen to the mean (three determinations) counts min-~ obtained in the absence of antigen.
RESULTS
Induction of anti-HBsAg antibodies
To study the effect of a free TDh sequence on the induction of anti-HBsAg antibodies SJL/J and B10M mice were immunized with a mixture of HBsAg (the recombinant product from Smith Kline and French, S.A., used for vaccination in humans) and the TDh peptide FIS, both emulsified in Freund's adjuvant as stated in Methods. We chose these strains because they are reported to be non-responders to HBsAg s'9 and it was known, from IL-2 production assays, that SJL/J but not B10M mice were able to recognize FIS as TDh peptide. Figure 1 shows that immunization of SJL/J mice with the recombinant HBsAg vaccine alone was unable to induce anti-HBsAg antibodies in ten out of ten immunized mice. However, immunizations of nine mice with the vaccine mixed with FIS in Freund's adjuvant rendered HBsAg immunogenic in seven of nine of the immunized mice. By contrast, immunization of B10M mice using the same strategies did not render any of these mice responders to HBsAg.
Mapping the specificity of anti-HBsAg with synthetic peptides
To map the linear regions of HBsAg, recognized by anti-HBsAg antibodies, we synthesized 47 overlapping 14-mer peptides, encompassing the entire S region (amino acids 175-400 of HBV surface protein) and tested them by ELISA against the antisera diluted 1/100 and 1/200. The recognition was considered positive only if the absorbances of the ELISA assay for serum dilutions 1/100 and 1/200 of immunized animals were at least four times the average absorbance of the corresponding dilution of the serum of a non-immunized animal. The antisera from SJL/J mice immunized with 1 #g HBsAg and 60/~g FIS were able to recognize several peptides. Most of the tested sera recognized peptides 290-303, 295-308 and the protein (see Table 1 and Figure 2 ).
T-cell response to antigens
To obtain an insight into which TD h was responsible for providing T-cell help to anti-HBsAg antibody production cells we immunized SJL/J and B10M mice with recombinant HBsAg vaccine alone and with vaccine Short paper: S. Hervas-Stubbs et al. ~Each number corresponds to the serum at day 60 of an immunized animal, Only sera with an anti-HBsAg antibody titre >3 are shown ~Titres were determined by the highest serum dilution to yield three times the absorbance of a negative serum and are expressed as the log of this dilution (D) CEach peptide is identified by the numbers of the N-terminal and C-terminal amino acids corresponding to its position within the sequence 1-400 of the HBV surface protein together with FIS in identical proportions to the ones used for antibody induction (see Methods). After removal of lymph nodes and plating of the lymphocytes, these were restimulated with FIS and with HBsAg.
Figure3
clearly shows that in the group of SJL/J mice immunized with HBsAg vaccine alone, neither FIS nor HBsAg is able to induce IL-2 production, except for a marginal signal at the higher dose of HBsAg. However, FIS but not HBsAg is able to induce IL-2 in the group of SJL/J immunized with the mixture of HBsAg and FIS. By contrast, neither of the two groups of B10M-immunized mice (with HBsAg alone and HBsAg in conjunction with FIS) was able to induce IL-2 production.
DISCUSSION FIS provides T-cell help to SJL/J mice and renders them responders to immunization with HBsAg
Induction of anti-HBsAg antibodies in SJL/J mice was only achieved by immunization with the antigen together with FIS ( Figure I ). As has been described before s'9 and is shown in Figure 3 , the S region of HBsAg is unable to induce a T-cell response in SJL/J mice. This explains why no humoral response against HBsAg was obtained in the group of mice immunized with the vaccine alone. However, joint immunization with FIS and HBsAg induces a T-cell response specific for FIS. This, together with the finding that anti-HBsAg antibodies are induced only following joint immunization with vcccine and FIS, proves that the T-cell help required to induce the humoral response against HBsAg must necessarily come from FIS. As suggested previously by this laboratory v, we believe that the effect of FIS might be due to direct binding of FIS to class II molecules of a physically close B cell having recognized an epitope (in the present case from HBsAg) via its surface immunoglobulin. Since direct binding would be favoured by an excess of FIS at the immunization site we have used a high ratio of this determinant with respect to HBsAg. We cannot provide a clear explanation for the lack of response of two mice from Figure 1 to combined immunization with HBsAg and FIS. However, it could be tentatively postulated to be due to variability between individuals.
FIS does not provide T-cell help to BIOM mice and thus cannot render them responders to immunization with HBsAg
As shown in Figure 1 , immunization of B10M mice with HBsAg in conjunction with FIS was unable to Figure 3 .
Indeed, the IL-2 production assay shows that, like SJL/J, B10M mice are unable to recognize any TD h sequence within the recombinant vaccine. Moreover, and in contrast to SJL/J mice, the strain B10M is unable to recognize FIS as a TDh peptide. Therefore, since FIS is not recognized as a TD h peptide, no T-cell help could be provided and consequently no anti-HBsAg antibodies could be induced. This also corroborates that the role of FIS in SJL/J is to provide specific T-cell help for the induction of antibodies.
Mapping the humorai response to HBsAg using synthetic peptides
As shown in Table 1 and Figure 2 , peptides 290-303
and 295-308 were the most commonly recognized among
Vaccine 1994 Volume 12 Number 10 869 the 47 14-mer peptides from the S region of HBV surface protein, a result in agreement with the reported evidence17 19 that the region 274-331 contains most of the B-cell recognition sites of the S region. Since antiserum 195 was able to recognize HBsAg but not any of the synthetic peptides encompassing this antigen, it would seem likely that the antibodies induced in this mouse may be directed against a conformational epitope of HBsAg not well presented by these short synthetic peptides, although it cannot be excluded that this lack of recognition could be associated with low affinity and/or low antibody titre of immunoglobulins of antiserum 195.
Potential applications of the study
The strategy of using FIS to potentiate the humorai response has proved to be very successful for other restrictions in our laboratory. Thus, we have induced antibodies in Balb/c mice against more than 100 haptenic peptides (data not shown). Also, in five of five peptides tested, this procedure was also successful in New Zealand white rabbits. We favour this method not only because it bypasses the need to couple the TDh peptide to the haptenic molecule, or macromolecule, but also, and perhaps more importantly, because it avoids the risk of inducing unwanted structural changes of relevant epitopes of the antigen due to the coupling of the TD h sequence. There is, however, a potential disadvantage in using the strategy of joint immunization with a TD h peptide not covalently linked to the hapten, namely the possibility of activating unwanted B lymphocytes specific for other antigens that might be present at the immunization site. Another interesting aspect of the strategy of joint immunization of hapten and TD h is that it offers the possibility of testing the ability of a TD h peptide to provide suitable T-cell help for antibody production in the context of a given restriction.
With respect to vaccination against HBV, it has been observed that a small proportion of humans are non-responders. This lack of response seems to be due to a lack of T-cell help and is associated with the restriction HLA-AI, B8 and DR32°'21. Moreover, this restriction is also associated with chronic active hepatitis 22'23. Our results of joint immunization with FIS and HBsAg vaccine obtained in SJL/J mice suggest that a similar strategy might be used to induce anti-HBsAg antibodies in those humans who do not respond to vaccination 2°'21 with this antigen. However, if the purpose of this immunization is to confer long-lasting protection against HBV infection, it might be more adequate to use a suitable TD h peptide from other antigens of the virus to induce memory T cells that could be activated following infection with HBV.
We believe that immunization with an antigen in conjunction with a suitable TD h peptide to overcome non-responsiveness, may make it possible to treat chronically infected patients such as, for instance, those infected by hepatitis B virus (HBV). Thus, if a strong antibody response against the HBV surface antigen could be induced in these patients (like the one observed in acute hepatitis B following seroconversion) the HBV might be cleared. We are starting experiments to try this hypothesis in an animal model.
